TH68221A - - Google Patents

Info

Publication number
TH68221A
TH68221A TH301004804A TH0301004804A TH68221A TH 68221 A TH68221 A TH 68221A TH 301004804 A TH301004804 A TH 301004804A TH 0301004804 A TH0301004804 A TH 0301004804A TH 68221 A TH68221 A TH 68221A
Authority
TH
Thailand
Prior art keywords
modulate
inhibit
compounds
proliferation
vascular
Prior art date
Application number
TH301004804A
Other languages
English (en)
Thai (th)
Original Assignee
นายจักรพรรดิ์ มงคลสิทธิ์ นางสาวปรับโยชน์ ศรีกิจจาภรณ์ นายบุญมา เตชะวณิช นายต่อพงศ์ โทณะวณิก
Filing date
Publication date
Application filed by นายจักรพรรดิ์ มงคลสิทธิ์ นางสาวปรับโยชน์ ศรีกิจจาภรณ์ นายบุญมา เตชะวณิช นายต่อพงศ์ โทณะวณิก filed Critical นายจักรพรรดิ์ มงคลสิทธิ์ นางสาวปรับโยชน์ ศรีกิจจาภรณ์ นายบุญมา เตชะวณิช นายต่อพงศ์ โทณะวณิก
Publication of TH68221A publication Critical patent/TH68221A/th

Links

TH301004804A 2003-12-18 TH68221A (enrdf_load_html_response)

Publications (1)

Publication Number Publication Date
TH68221A true TH68221A (enrdf_load_html_response) 2005-04-20

Family

ID=

Similar Documents

Publication Publication Date Title
Rudolph et al. Inhibitors of p21-activated kinases (PAKs) miniperspective
McKernan et al. Protein kinase C: one pathway towards the eradication of latent HIV‐1 reservoirs
Karin et al. The IKK NF-κB system: a treasure trove for drug development
RS20050430A (en) 2-(1h-indazol-6-ylamino)-benzamide compounds as protein kinases inhibitors useful for the treatment of ophtalmic diseases
Chmurska et al. Two faces of autophagy in the struggle against cancer
HUP0203965A2 (en) Indazole compounds and pharmaceutical compositions containing them
CY1107148T1 (el) Παραγωγα ινδαζολης και φαρμακευτικες συνθεσεις για αναστολη των κινασων πρωτεϊνης και μεθοδοι για τη χρηση τους
BRPI0410563A (pt) derivados de pirazol-quinazolina processo para sua preparação e seu uso como inibidores de quinase
SV2003001148A (es) Derivados de benzamida tiazol y composciones farmaceuticas para inhibir la proliferacion de celulas, y metodos para su utilizacion ref. no.0097-01-sv
EA201070167A1 (ru) Замещенные производные индазола, активные как ингибиторы киназы
EA200400953A1 (ru) Замещённые пиридиноны в качестве модуляторов map-киназы p38
Dent et al. Neratinib degrades MST4 via autophagy that reduces membrane stiffness and is essential for the inactivation of PI3K, ERK1/2, and YAP/TAZ signaling
BR0312722A (pt) Derivados de pirazol heterobicìclico como inibidores de qinase
BRPI0517921A (pt) métodos para preparar compostos de indazol
Ciarlantini et al. Development of an Improved Guanidine‐Based Rac1 Inhibitor with in vivo Activity against Non‐Small Cell Lung Cancer
CN109640970A (zh) 具有内皮稳定化活性和抗炎活性的非催化底物选择性p38α特异性MAPK抑制剂及其使用方法
Hatcher et al. Discovery of a selective, covalent IRAK1 inhibitor with antiproliferative activity in MYD88 mutated B-cell lymphoma
Berabez et al. LIM kinases, promising but reluctant therapeutic targets: chemistry and preclinical validation in vivo
EA200401319A1 (ru) Новые гетероциклические соединения, способы их получения и фармацевтические композиции, содержащие эти соединения, и их использование в медицине
Kekeçmuhammed et al. Synthesis, Biological Activity Evaluation and Molecular Docking of imidazole derivatives possessing hydrazone moiety
Mancini et al. 14‐3‐3 ligand prevents nuclear import of c‐ABL protein in chronic myeloid leukemia
TH68221A (enrdf_load_html_response)
Dravecka et al. Low extracellular pH protects cancer cells from ammonia toxicity
Mao et al. JWA is required for the antiproliferative and pro‐apoptotic effects of all‐trans retinoic acid in Hela cells
Osmaniye et al. Synthesis of Imidazole‐2, 3‐dihydrothiazole Compounds as VEGFR‐2 inhibitors and their support with in silico studies